Novotiss strives to raise the quality of postoperative care through surgical sealing innovations that can transform tissue adhesives into a reliable alternative to suturing. As a medical device, tissue adhesives have been gradually replacing sutures because of several advantages that can be summarized into minimal invasiveness, sealing efficacy, ease of use, low cost, and patient comfort. The startup company focuses on product development of these tissue adhesives to explore more advanced functionalities that can answer specific clinical needs that limit the use of such a relatively young technology. The company is formed to commercialize technologies and expand the product line developed in the laboratory after years of hard work by HKUST researchers. The rapidly ageing population especially in Asia, the rising cases of chronic diseases, and the global shift to minimally invasive procedures provide huge market opportunities for the operation of Novotiss.